Bayer announced today that data from 13 new analyses from across the KERENDIA® (finerenone) comprehensive clinical trial program will be presented at the American College of Cardiology (ACC) 74th ...

Bayer announced today that data from 13 new analyses from across the KERENDIA® (finerenone) comprehensive clinical trial program will be presented at the American College of Cardiology (ACC ...

Bayer's mineralocorticoid receptor antagonist (MRA) Kerendia hit the mark as a treatment for a common form of heart failure in the FINEARTS-HF study, setting up regulatory approvals, but there is ...

Bayer has emphasises that Kerendia works in a different way to the SGLT2 drugs by blocking MR overactivation, which it says is a key driver of CKD progression. Overactivation of the system ...

The company is working to expand the labels of its key drugs, Nubeqa and Kerendia, which should boost growth. Successful development of additional drugs is imperative for Bayer amid multiple ...

Finereone is currently approved under the brand name Kerendia ® to reduce the risk of sustained estimated glomerular filtration rate decline, end stage kidney disease, CV death, nonfatal ...

The stock has lost 12.5% so far this year. Price and Consensus: NVO Bayer: The company’s key drugs, Nubeqa for cancer and Kerendia for chronic kidney disease associated with type II diabetes ...

The drug and biotech sector has recovered over the past couple of months, following a slow start to the year, primarily due ...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that data from 13 new analyses from across the KERENDIA® (finerenone) comprehensive clinical trial program will be presented at the American ...